Chronic inflammatory bowel disease (IBD) presents a profound medical challenge, characterized not only by the intensity of its symptoms but also by the long-term risk of severe complications, including the development of bowel cancer. For many, the diagnosis comes at a pivotal moment in life. When genetic predisposition intersects with specific environmental triggers, conditions such as ulcerative colitis or Crohn’s disease frequently manifest between the ages of 15 and 29—a critical window that often coincides with the formative years of higher education and the early stages of professional career development. Given the life-altering nature of these conditions, the urgency for prompt, accurate diagnosis and effective, long-term treatment remains a primary focus for the medical community.
Researchers at Charité – Universitätsmedizin Berlin have now achieved a significant milestone in this pursuit. The team has identified a specific therapeutic target that plays a decisive role in fueling ongoing inflammatory processes within the gut. Their findings, which offer a promising new avenue for clinical intervention, have been published in the current issue of the prestigious journal Nature Immunology.
Understanding the Burden of Chronic Inflammation
The onset of chronic inflammatory bowel diseases is often insidious, marked by a progression that can be gradual or punctuated by sudden, debilitating flare-ups. Patients frequently endure a spectrum of distressing symptoms, including severe abdominal cramps, chronic diarrhea, significant weight loss, persistent fatigue, and a high level of emotional and psychological stress.
While the two most common forms of IBD—ulcerative colitis and Crohn’s disease—share many clinical features, they differ in their anatomical presentation. Ulcerative colitis is typically confined to the inner lining of the large intestine. In contrast, Crohn’s disease is more systemic in its potential reach, often involving the entire thickness of the intestinal wall. While it most commonly affects the small intestine, it can also manifest in the stomach and esophagus. Beyond the immediate discomfort, the ongoing, chronic inflammation causes lasting tissue damage and significantly elevates the long-term risk of developing cancer.
Historically, the medical approach to managing these diseases has relied on immunosuppressive therapies designed to dampen the immune system as a whole. However, as our understanding of immunology has evolved, so too have therapeutic strategies. Modern medicine is increasingly pivoting toward targeted therapies that function by interrupting the specific inflammatory cascade at its source, effectively blocking the messenger substances that drive the body’s overactive immune response.
The Mystery of Causation and the Role of Immune Messengers
Despite advancements in medical research, the precise etiology of severe systemic inflammatory diseases remains a subject of intense investigation. It is widely accepted that these conditions are multifactorial, arising from a complex interplay between genetic susceptibility and environmental influences. Prof. Ahmed Hegazy, a researcher at Charité’s Department of Gastroenterology, Infectiology, and Rheumatology, has dedicated years to mapping the intricate defensive mechanisms of the immune system and the inflammatory processes that occur within the gut.
In a collaborative effort with his research team, Prof. Hegazy has successfully pinpointed the interaction between two specific immune system messenger substances as the primary driver behind chronic intestinal inflammation. These two proteins are Interleukin-22, which typically functions to support the epithelial cells lining the gut and maintain the integrity of the protective intestinal barrier, and oncostatin M, a signaling molecule known for its role in tissue repair and cell differentiation.
Uncontrolled Chain Reactions in the Gut
For clinicians like Prof. Hegazy, the human element of this research is never far from mind. "At the clinic, we mainly see young patients who are just beginning their professional lives," he notes. "So far, we have only been able to slow down the progression of the disease and alleviate symptoms. But not all patients respond well to existing treatments, so new therapeutic approaches are urgently needed."
The research team’s breakthrough came after they focused their attention on the behavior of oncostatin M. Previously, the team had identified this protein as a significant inflammation-promoting messenger. Produced by certain immune cells, oncostatin M acts as a catalyst, activating other inflammatory factors and setting off a chain reaction that results in an excessive and damaging immune response.
"It was especially interesting for us to see that patients with high levels of oncostatin M do not respond to several common therapies," Prof. Hegazy explains. This observation led the team to a critical conclusion: levels of oncostatin M could potentially serve as a biomarker for more severe forms of the disease, helping clinicians predict which patients might experience treatment failure. With this insight, the team focused their efforts on better understanding this signaling pathway to develop methods to block it through targeted therapy.
Mapping the Signaling Pathway
Over a five-year period, the team worked to uncover the mechanisms by which oncostatin M triggers inflammatory responses. Utilizing a combination of animal models and patient tissue samples, the researchers examined the various stages of chronic intestinal disease. By employing state-of-the-art single-cell sequencing, they were able to observe the cellular landscape of the gut in unprecedented detail.
The findings were striking: compared to healthy tissue, the inflamed gut displayed a significantly higher number of cell types that possessed binding sites, or receptors, for oncostatin M. Simultaneously, the researchers observed that an increased number of immune cells began producing the inflammatory protein.
Perhaps most surprising was the discovery regarding the role of Interleukin-22. While this protein is typically understood to be protective, the researchers found that it inadvertently makes the gut lining more sensitive to oncostatin M by increasing the number of available receptors for the molecule. "These two immune messengers work together and amplify the inflammation, drawing more immune cells into the intestine, like a fire that keeps getting more fuel and spreads," Prof. Hegazy says. Through their experimental models, the researchers were able to specifically block these receptors for oncostatin M, resulting in a clear reduction in both the intensity of chronic inflammation and the associated risk of cancer.
Targeted Therapy for High-Risk Patients
The clinical implications of these findings are significant. When examining tissue samples from patients with colorectal cancer caused by chronic intestinal inflammation, the researchers found a particularly high concentration of receptors for oncostatin M around the tumors, a feature entirely absent in surrounding healthy tissue. This suggests that the signaling pathway in question is a direct promoter of cancer development in the context of chronic inflammation.
However, the team remains cautious, acknowledging the complexity of the disease. "Chronic inflammatory bowel diseases are highly complex and differ from person to person," says Prof. Britta Siegmund, Director of the Clinic for Gastroenterology, Infectiology, and Rheumatology. "That’s exactly what makes them so difficult to treat and predict treatment. Thanks to the role of oncostatin M and its amplifying interaction with interleukin-22, which we have now identified, we have a clearer understanding of what drives chronic inflammation in some patients. This opens up the door to developing and testing a new therapeutic approach."
The team’s experimental success is already beginning to transition toward real-world applications. By specifically disrupting the harmful interaction between Interleukin-22 and oncostatin M, researchers hope to provide a new standard of care for those suffering from severe forms of the illness. "Our results provide a strong scientific basis for developing targeted treatments against this inflammation-promoting mechanism in chronic inflammatory bowel disease," Prof. Hegazy concludes. Currently, a clinical trial is underway to test an antibody that specifically blocks the receptors for oncostatin M, offering a beacon of hope for patients who have previously found little relief from traditional medical interventions.